The development of immune checkpoint blockade, which disrupts the interaction between PD-1 and CTLA4 on T cells with their respective ligands to reverse exhaustion caused by chronic antigen exposure, has been an important addition to the arsenal of treatments for several cancers, including melanoma, lung cancer, and bladder cancer (55). Here, CTLA4 is linked to urinary bladder carcinoma.